Compare VABK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | DTIL |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.3M | 185.3M |
| IPO Year | 2013 | 2019 |
| Metric | VABK | DTIL |
|---|---|---|
| Price | $43.40 | $6.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 2.9K | ★ 323.4K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.70 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.48 | $3.53 |
| 52 Week High | $48.58 | $8.82 |
| Indicator | VABK | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 50.21 |
| Support Level | $37.99 | $6.58 |
| Resistance Level | $48.58 | $8.12 |
| Average True Range (ATR) | 0.75 | 0.61 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 100.00 | 45.05 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).